THE STRUCTURE OF DRUG PRESCRIPTION IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION ON THE FIRST DAY OF HOSPITAL THERAPY
https://doi.org/10.20996/1819-6446-2009-5-2-8-17
Abstract
Aim. To evaluate the structure of drug prescriptions in acute coronary syndrome (acute myocardial infarction and unstable angina) on the first day of hospital therapy in Saratov city and Saratov region.
Material and methods. Retrospective pharmacoepidemiology study was carried out in 1276 patients with acute coronary syndrome (ACS) without elevation ST during first 24 hours.
Results. Prescription of drugs with proven efficacy in ACS was higher in Saratov city clinical hospital than this in Saratov municipal hospital or hospitals of Saratov region. There were no significant differences in drug prescriptions in Saratov municipal hospital and hospitals of Saratov region.
Conclusion. The first day therapy of ACS depends on hospital type.
About the Authors
O. V. Reshetko
Saratov Scientific Research Institute for Cardiology of Rosmedtechnology
Russian Federation
Russian Federation
Chernyshevskogo ul. 141, Saratov, 410028
N. V. Furman
Saratov Scientific Research Institute for Cardiology of Rosmedtechnology
Russian Federation
Russian Federation
Chernyshevskogo ul. 141, Saratov, 410028
R. M. Magdeev
Saratov Scientific Research Institute for Cardiology of Rosmedtechnology
Russian Federation
Russian Federation
Chernyshevskogo ul. 141, Saratov, 410028
References
1. Daly C., Clemens F., Lopez-Sendon J. L. et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006;27(11):1298-304.
2. Fox K.A., Goodman S.G., Anderson F.A. Jr et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24(15):1414-24.
3. Mandelzweig L., Battler A., Boyko V. et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27(19):2285-93.
4. Hasdai D., Behar S., Wallentin L. et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in European and Mediterranean basin: The Euro Heart Survey Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23(15):1190-201.
5. Belenkov Iu.N., Mareev V.Iu. How we treat patients with cardiovascular diseases in real clinical practice. Ter Arkh. 2003;75(8):5-11. [Беленков Ю.Н., Мареев В.Ю. Как мы лечим больных с сердечно-сосудистыми заболеваниями в реальной клинической практике. Тер арх 2003;(8):5-11].
6. Fox K.A., Goodman S.G., Klein W. et al. Management of acute coronary syndromes. Variations in practice and outcome: Findings from the Global Registry of the Acute Coronary Events (GRACE). Eur Heart J 2002;23(15):1177-89.
7. Giugliano R. P., Llevadot J., Wilcox R. G. et al. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis Results from InTIME-II. Eur Heart J 2001;22(18):1702-15.
8. Kramer J.M., Newby L.K., Chang W.C. et al. International variation in the use of evidence- based medicines for acute coronary syndrome. Eur Heart J 2003;24(23):2133-41.
9. Reed S.D., McMurray J.J., Velazquez E.J. et al. Geographic Variation in the Treatment of Acute Myocardial Infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial. Am Heart J 2006;152(3):500-508.
10. Orlandini A., Diaz R., Wojdyla D. et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J 2006;27(5):527-33
11. Jonsson L., Lundborg C.S. Exploring unexplained twofold differences in sales of cardiovascular drugs between two neighbouring Swedish municipalities. Pharmacoepidemiol Drug Saf 2005;14(5):349-55.
12. Zaharevich O.A., Leonova M.V. Pharmacoepidemiologic study of physicians' adherence to high pressure lowering drugs prescription. Kachestvennaya Klinicheskaya Praktika 2001;(1):61-4. [Захаревич О.А., Леонова М.В. Фармакоэпидемиологическое исследование приверженности врачей к назначению гипотензивных лекарственных средств. Качественная клиническая практика 2001;(1):61-4].
13. Belousov Iu.B., Leonova M.V., Belousov D.Iu. Hypertensive patients in Russia, pharmacoepidemiological study results (PIFAGOR II). Kachestvennaya Klinicheskaya Praktika 2004;(1):17- 7. [Белоусов Ю.Б., Леонова М.В., Белоусов Д.Ю. и др. Результаты фармакоэпидемио- логического исследования больных артериальной гипертонией в России (ПИФАГОР II). Качественная клиническая практика 2004;(1):17-7.]
14. Petrov V.I., Nedogoda S.V., Lopatin Iu.M. et al. Pharmacoepidemiology of high pressure lowering agents in Volgograd area. Klinicheskaya Farmakologiya I Terapiya 2002;(11):62-5. [Петров В.И., Недогода С.В., Лопатин Ю.М. и др. Фармакоэпидемиология антигипертензивных препаратов в Волгоградской области. Клин фармакол тер 2002;(11):62-5.]
15. Fomin I.V., Mareev V.Iu., Fadeeva I.P. et al. Real prevalence of hypertension and contemporary state of high pressure lowering treatment in Nizhny Novgorod area (Register 1988 data). Kardiologiia 2000;(8):34-6. [Фомин И.В., Мареев В.Ю., Фадеева И.П. и др. Истинная распространенность артериальной гипертонии и современное состояние гипотензивной терапии в Нижегородской области (данные Регистра 1998 г.). Кардиология 2000;(8):34-6.]
16. Khohlov A.L., Lisenkova L.A., Rakov A.A. Analysis of factors, determining antihypertensive treatment adherence. Kachestvennaya Klinicheskaya Praktika 2003;(4):59-66. [Хохлов А.Л., Ли- сенкова Л.А., Раков А.А. Анализ факторов, определяющих приверженность к антигипертензивной терапии. Качественная клиническая практика 2003;(4):59-66.]
17. Iavelov I.S., Gratsianskii N.A. Register of acute coronary syndromes in Russia: treatment and in hospital outcomes in non-ST elevation acute coronary syndrome. Kardiologiia 2003;43(12):23- 36. [Явелов И.С., Грацианский Н.А. Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме без подъемов сегмента ST. Кардиология 2003;(12):23-36.]
18. Society of Cardiology of the Russian Federation. Non-ST-elevation acute coronary syndrome treatment guidelines. Edition 2003. Cardiovascular Therapy and Prevention 2004;4(supplement):1- 42. [Всероссийское научное общество кардиологов. Рекомендации по лечению острого коронарного синдрома без стойкого подъема сегмента ST на ЭКГ. Редакция 2003. Кардиоваск тер профилакт 2004;4(приложение):1-42.]
19. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-elevation acute coronary syndromes. Eur Heart J 2007;28(13):1598-660.
20. Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction). Circulation 2007;116(7):e148–e304.
21. Staroverov I.I. -blockers at acute coronary syndrome. Serdtse 2002;1(1):42-3. [Староверов И.И. -блокаторы при остром коронарном синдроме. Сердце 2002;1(1):42-3.]
22. The Task Force on Beta–Blockers of the European Society of Cardiology. Expert consensus document on beta–adrenergic receptor blockers. Eur Heart J 2004;25(15):1341-62.
23. Patrono C., Bachmann F., Baigent C. et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25(2):166-81.
24. Nikiforov Yu.V., Spirochkin D.Yu. Anaesthesia in acute coronary syndrome. Russian Journal of Cardiology 2004;(2):80-6 [Никифоров Ю.В., Спирочкин Д.Ю. Обезболивание при остром коронарном синдроме. Российский кардиологический журнал 2004;(2):80-6.]
25. Reshetko O.V., Magdeev R.M., Furman N.V. Analysis of acute coronary syndrome pre-hospital treatment. Rational Pharmacotherapy in Cardiology 2007;(5):4-7. [Решетько О.В., Магдеев Р.М., Фурман Н.В. Анализ фармакотерапии острого коронарного синдрома на догоспитальном этапе лечения. Рациональная Фармакотерапия в Кардиологии 2007;(5):4-7.]
26. Lpez-Sendn J., Swedberg K., McMurray J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25(16):1454-70.
27. Sergeev Iu.D., Bisiuk Iu.V. The juridical significance of primary medical documentation. Klin Med (Mosk) 2007;85(12):72-3. [Сергеев Ю.Д., Бисюк Ю.В. Юридическое значение первичной медицинской документации. Клин мед 2007;(12):72-73.]
28. Segev A., Strauss B.H., Tan M. Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries). Am J Cardiol 2006;98(4):470-3.
Review
For citations:
Reshetko O.V., Furman N.V., Magdeev R.M. THE STRUCTURE OF DRUG PRESCRIPTION IN ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION ON THE FIRST DAY OF HOSPITAL THERAPY. Rational Pharmacotherapy in Cardiology. 2009;5(2):8-17. https://doi.org/10.20996/1819-6446-2009-5-2-8-17
Views: 612
Email this article 